STUDY QUESTION: Is female infertility associated with higher risk of cancer?
Introduction
The association between infertility and the risk of developing a malignancy is an ongoing concern for both fertility patients and providers.
Several studies suggest that infertile women are at higher risk of cancer than women from the general population, particularly hormonesensitive cancers of the breast, ovaries and endometrium (Brinton et al., 1989; Rossing et al., 1994; Venn et al., 1995; Meirow and Schenker, 1996; Modan et al., 1998; Althius et al., 2005b; Rizzuto et al., 2013; Practice Committee of ASRM, 2016; Skalkidou et al., 2017; Williams et al., 2018) . There is some conflicting data, however, from additional studies showing no association between infertility and risk of breast and ovarian cancer (Venn et al., 1995; Kashyap et al., 2004; Jensen et al., 2007; van den Belt-Dusebout et al., 2016) . Less is known about risks of non-gynecologic malignancies among infertile patients (Althius et al., 2005b; Calderon-Margalit et al., 2009) . For all cancer types, the low incidence of malignancy in reproductive age women limits the conclusions of the majority of studies' risk associations. Furthermore, the effect of pregnancy on the risk association between infertility and cancer has been investigated for only a minority of cancer types (Nagasue et al., 1986; Dupont and Page, 1987; Adami et al., 1994; Lambe et al., 1999; Kreuzer et al., 2003; Giannitrapani et al., 2006) .
The objective of our study was to investigate whether infertility was associated with a subsequent risk of developing a malignancy. In addition, we sought to investigate the effect, if any, of pregnancy on the risk association between infertility and cancer. In order to overcome the low incidence of cancer in women of reproductive age, we used a large database of health insurance claims to examine outcomes in infertile patients as many insurance organizations offer coverage for infertility testing and treatment.
Medicare Advantage health plan data. The population is geographically diverse, spanning all 50 states. This study was approved by the Stanford Institutional Review Board.
Given the variation in infertility coding and reimbursement practices in the USA, we attempted to be as broad as possible. The cohort of infertile women was comprised of women receiving any of the following: (i) an infertility diagnosis, (ii) fertility testing or (iii) fertility treatment. Women with an infertility diagnosis were identified by outpatient claims (ICD9: 628.x, 614.6, V26.89, ICD10: E23.0, N73.6, N97.x, Z31.81). Fertility testing was identified through diagnosis codes (V26.21, Z31.41) or the presence of a procedure code (CPT) for hysterosalpingogram (HSG) (74740). HSG was chosen to identify infertile women because it is commonly ordered as part of an initial fertility evaluation to assess tubal patency but is not otherwise part of routine gynecologic care (Crosignani and Rubin, 2000) . Patients receiving fertility treatment were identified by the presence of a CPT code for intrauterine artificial insemination (58322), follicular puncture for oocyte retrieval (58970) or intrauterine embryo transfer (58974) . The presence of a pharmacy claim for a prescription for clomiphene citrate or a gonadotropin (FSH, HMG, HCG) was also used to identify patients receiving fertility treatment. Clomiphene was chosen because it is routinely used to induce ovulation for women with anovulatory infertility as well as to promote superovulation for women who are ovulatory, and is not prescribed for non-fertility indications (Kousta et al., 1997) .
Gonadotropins (FSH, HMG, HCG) have comprised the standard approach for ovulation stimulation and induction for ART since they were first implemented in 1981 and HCG has consistently been used to mimic the midcycle surge in luteinizing hormone that triggers final oocyte maturation in ART cycles (Lunenfeld, 2012) .
The comparison group was composed of women receiving routine gynecologic care who did not have an infertility diagnosis or procedure codes for fertility testing or treatment. These patients were identified through the presence of a claim for a well woman visit (V72.31, Z01.411, Z01.419), encounter for contraceptive management (V25.0, V25.01-V25.04, V25.09, Z30.011, Z30.012, Z30.015, Z30.016, Z30.017, Z30.018, Z30.02, Z30.09), encounter for placement or removal of an Z30.430, Z30.432, Z30.433) , encounter for placement of a contraceptive implant (V25.5, Z30.8), encounter for bilateral tubal ligation (V25.2, Z30.2), encounter for contraceptive surveillance (V25. 40-V25.43, V25.49, Z30.40, Z30.41, Z30.42, Z30.431, Z30.436, Z30.44, Z30.45, Z30.49 ) and encounter for pap smear (V72.32, Z12.4, 88141-88155, 88164-88167, 88174-5, Q0091, G0101) .
In both groups, women who became pregnant and had a delivery were identified by diagnosis and procedure codes indicating the end of a pregnancy. These diagnosis and procedure codes were obtained from a literature search of insurance claims data used to identify various pregnancy outcomes (Bennett et al., 2014; Ailes et al., 2016) and are listed in Supplementary Table SI. We recorded the first date of a relevant diagnosis or procedure code as the index date. For patients in the infertile group, index date was the date of infertility diagnosis, testing or treatment. For patients in the non-infertile group, index date was the date of encounter for any of the services listed above. In order to be included in the study, patients were required to be enrolled in a plan covered by the database for at least 6 months before and after the index date. Patients were also required to be between 20 and 45 years old on the index date. In all groups, patients with a prior cancer diagnosis or with a cancer diagnosis within the 6 months following the index date were excluded from the study. This was identified through the presence of any claim with a diagnosis code for cancer.
Outcome ascertainment
Cancer diagnoses were identified using diagnosis codes on inpatient and outpatient claims. Diagnosis codes to identify cancer were aligned to the Surveillance, Epidemiology, and End Results (SEER) definitions. We identified patients with claims diagnoses indicating the presence of any invasive cancer excluding non-invasive cancers, skin squamous cell and skin basal cell cancers (ICD9: 140-209, C00.x-C96.x). We also identified the presence of specific cancers including upper respiratory (140.x-149.x, 160.x, 161.x, C00.x-C14.x, C30.x, C31.x, C32.x), stomach (151.x, C16.x), colorectal (153.x, 154.0, 154.1, 154.8, C18.x, C218.x, C19.x, C20.x), liver and gallbladder (155.x, 156.x, C22.x, C23.x), pancreas (157.x, C25.x), lung (162.x, C33.x, C34.x), melanoma (172.x, C43.x, D03.x), breast (174.x, C50.019, C50.119, C50.219, C50.319, C50.419, C50.519. C50.619, C50.819, C50.919), bladder (188.x, C67.x), kidney (189.0, 189.1, C64.9x, C65.9x), brain and nervous system (191.x, 192.x, C71.x, C72.50x, C72.1x, C70.0x, C70.1x, C70.9x, C72.9x, C72.0x), thyroid (193.x, C73. x), 202.x), Hodgkin lymphoma (201.x, C81.x), leukemia (204.x, 205.x, 206.x, 207.x, 208.x, C91.x, C92.x, C93.x, C94.x. C95.x), esophagus (150.x, C15.x), uterus (179.x, 182.x, C55.x, C54.0x, C54.1x, C54.2x, C54.3x, C54.8x, C54.9x), cervix (180.x, C53.0x, C53.1x, C53.8x, C53.9x), and ovary (183.x, C56.9x, C57.3x, C57.4x, C57.00x, C57.10x, C57.20x) . Outcomes with <11 absolute number of events are required to be reported as <11 to protect patient privacy per the data usage agreement with Optum.
Several subset analyses were performed as follows: including only women in both infertile and non-infertile cohorts who became pregnant and had a delivery during the enrollment period, excluding women with PCOS (identified with diagnosis codes 256.4, 628.0, N97.0, E28.2) and endometriosis (identified with diagnosis codes 617.0, N80.9) from both infertile and non-infertile cohorts, and limiting follow up of all women to >2, >3 and >4 years. For all subset analyses, the incidence of a cancer diagnosis was compared between infertile and non-infertile cohorts.
Confounder selection
Cancer risk has been attributed in the literature to a variety of demographic factors including age, year of presentation, reproductive history, access to care, race, smoking, obesity and highest level of education (American Cancer Society, 2019) . Detection of cancer is also influenced by screening practices including screening mammography (Tabar et al., 1985) . In the Optum database, several demographic factors are available including age, year of diagnosis, race and highest level of education are available and were recorded at the index date. For each patient, diagnosis codes were then used to identify obesity (278.0, E66.9, E66.01, E66.3, E66.2), smoking (305.1, V15.82, F17.200, Z87.891), and nulliparity (V22.0, V23.81, V23.83, O0.95, O0.96) . Diagnosis codes entered either at the index date or during the follow up period were included. As a proxy measure of access to care, for each patient, the number of outpatient visits after the index date was determined based on the presence of claims for CPT codes indicating new and follow up visits, consultations, or preventive medicine encounters. For patients with a diagnosis of breast cancer, those who obtained a screening mammogram prior to cancer diagnosis were identified using codes (ICD-10: Z12.31, ICD-9: V76.11, CPT: 77067, 77066, 77065, 77063, HCPCS: G0202, G0204, G0206).
Statistical analysis
To compare demographics between infertile and non-infertile cohorts, the Chi-square test was used for categorical variables, Student's T-test was used to compare age, and the Wilcoxon rank-sum test was used to compare follow up time and number of visits. Patients accrued at risk time beginning from their index dates until cancer diagnosis or the last enrollment date in a health plan in the Optum ® insurance claims database. The risk of cancer between infertile patients and the non-infertile group was assessed using a Cox proportional hazards model while adjusting for age at index date, index year, nulliparity, race, smoking, obesity, number of visits per year and highest level of education. Risk of breast cancer was also adjusted for receiving a screening mammogram. All p values were 2-sided with P < 0.05 considered statistically significant. Analyses were performed using SAS (version 9.4, SAS Institute, Inc., Cary, NC, USA).
Results

Patient demographics: infertile versus non-infertile patients
Overall, 64 345 patients had a diagnosis of infertility, underwent fertility testing or underwent fertility treatment. The non-infertile group was comprised of 3 128 345 patients who were deemed non-infertile. Patients in the infertile group were older on average at the index date (34.0 ± 5.7 years) compared to the non-infertile group (32.7 ± 7.4 years) (P < 0.0001). Patients were, on average, followed for 3.8 ± 3.3 years in the infertile group and 3.9 ± 3.3 years in the non-infertile group. In the study interval, there were 246 485 person-years of follow up in the infertile group and 12 268 968 person-years of follow up in the non-infertile group. Infertile patients were more likely to be nulliparous, obese and smokers compared to non-infertile patients (P < 0.0001 for all comparisons) ( Table I) . Infertile patients had a higher median number of visits per person per year (4.1 visits) compared to the non-infertile group (2.7 visits) (P < 0.0001). In both groups, the majority of patients were Caucasian. Education level, income and geographic distribution were similar between the infertile and noninfertile groups. Comparison of all demographics between infertile and non-infertile cohorts was significant (P < 0.001), likely due to the large sample size.
Patient demographics: subset of patients with a delivery
Of the 64 345 patients in the infertile group, 22 024 (34.2%) had a pregnancy and subsequent delivery during the enrollment period (4.5 ± 3.3 years). Of the 3 128 345 patients in the non-infertile group, 626 532 (20.0%) had a pregnancy and subsequent delivery during the enrollment period (4.5 ± 3.4 years). A higher proportion of women became pregnant and delivered in the infertile cohort compared to the non-infertile cohort. Infertile patients were older on average at time of follow up (32.6 ± 4.9 years) compared to non-infertile patients (29.8 ± 5.2 years) ( Table I ). Infertile patients in the delivery subgroup were more likely to be nulliparous and obese and less likely to be smokers compared to non-infertile patients.
Overall incidence of cancer across study cohorts
During follow up, there were 1310 cancer diagnoses in the infertile group and 53 116 cancer diagnoses in the non-infertile group. In both groups, the most common cancer diagnosed was breast (329 cases in the infertile group and 15 348 cases in the non-infertile group) ( Table II) .
Comparison of infertile and non-infertile cohorts
Women with infertility had an overall higher risk of developing cancer compared to non-infertile women (2.0 versus 1.7%, adjusted hazard ratio (aHR) = 1.18; CI: 1.12-1.24). In addition, the risk of uterine cancer (0.10 versus 0.06%, aHR = 
Subset analysis of patients with a delivery during enrollment
A subset analysis of cancer incidence in women who became pregnant and had a delivery in both the infertile and non-infertile groups was performed. The overall risk of cancer was higher in the infertile subgroup (1.78 versus 1.16%, aHR = 1.18; CI: 1.06-1.30), however, some associations were lower in magnitude (Table III) Subset analysis excluding patients with PCOS and endometriosis from both cohorts
In the infertile cohort, 36.3% of patients had a diagnosis of PCOS or endometriosis. In the non-infertile group, 4.0% of patients had a diagnosis of PCOS or endometriosis. A subset analysis was performed excluding patients with PCOS and endometriosis from both infertile and non-infertile cohorts. The overall risk of cancer was higher in the infertile subgroup (1.91 versus 1.63%, aHR = 1.14; CI: 1.06-1.22). Risk associations of individual cancers followed the same trends as the overall analysis with the exception of uterine cancer which did not differ between this infertile and non-infertile subgroup (0.05 versus 0.05%, aHR = 0.99; CI: 0.64-1.55).
Subset analysis limiting follow up time in both cohorts
The mean follow up time for both infertile and non-infertile cohorts was 3.9 years. A subset analysis was performed limiting follow up time to >2, >3 and >4 years in both infertile and non-infertile cohorts. The overall risk of any malignancy and risks of individual cancers was unchanged between the infertile and non-infertile subgroups compared to the overall analysis (data not shown).
Discussion
Although the overall incidence of cancer is low for all women in the cohort, we identify an association between infertility and higher risk of cancer compared to a group of non-infertile women.
Comparison of infertile and non-infertile cohorts
Higher risk of cancer in infertile women compared to the general population has been demonstrated in several prior studies. In particular, the risk of developing hormone-sensitive cancers of the breast, ovaries and uterus has previously been reported in infertile patients and attributed to anovulation and dysregulation of estradiol and progesterone levels (Brinton et al., 1989; Rossing et al., 1994; Venn et al., 1995; Meirow and Schenker, 1996; Modan et al., 1998) . During fertility treatment, estradiol and progesterone levels are upregulated above physiologic levels (Joo et al., 2010); therefore, concern has also been raised regarding fertility treatment and the risk of developing hormonesensitive cancers. For example, the incidence of uterine cancer was found to be higher after clomiphene treatment, with the strongest correlation in obese and nulliparous women (Althius et al., 2005a) . In both infertile and non-infertile patients, we report a low, overall absolute risk of cancer (2.04 and 1.70%, respectively). Comparison of cancer risk between infertile and non-infertile groups reveals an 18% higher risk of cancer among infertile patients compared to non-infertile patients. The low overall incidence, however, translates into a very modest increase in absolute risk of 1/49 compared to 1/59 for infertile and non-infertile patients, respectively. Given the overall risk association, we then sought to identify individual cancers risk associations. Among infertile patients, we report a higher risk of ovarian and uterine cancers and a similar risk of breast cancer compared to non-infertile patients. Furthermore, we report a higher risk of non-hormonal cancers including lung cancer, thyroid cancer, liver and gallbladder cancer and leukemia in the infertile group compared to non-infertile patients. While several associations were significant, absolute increases in risk were modest due to the low overall incidence of cancer in our patient cohort.
Subset analyses
Cancers typically develop over several years, and occult carcinomas may impair fertility for several years before clinical detection (Levanon et al., 2008) . Cancer risk has also been widely associated with several demographic factors (American Cancer Society, 2019). Infertile patients had higher rates of obesity and smoking compared to noninfertile patients, both of which can increase the risk of cancer (Bianchini et al., 2002; Bach et al., 2003) and therefore were controlled for in our statistical analysis. A secondary analysis in which obesity and smoking were excluded as potential confounders resulted in similar point estimates to the overall analysis. Infertile patients were, on average, older than non-infertile patients at the index date, however, the mean age difference of 1.3 years is unlikely to be clinically significant. Patients in the infertile group did have a higher number of visits per year compared to the non-infertile group, and perhaps were more likely to report symptoms that eventually led to a cancer diagnosis. Infertile patients may also have additional comorbidities that were not controlled for in the analysis and may result in higher risk of cancer. For example, PCOS has been consistently associated with increased risk of uterine cancer and sporadically associated with increased risk of breast and ovarian cancer (Balen, 2001; Dumesic and Lobo, 2013; Barry et al., 2014) . Endometriosis has been associated with increased risk of ovarian cancer (Somigliana et al., 2006) . In a subgroup analysis excluding patients with PCOS and endometriosis, we identified similar point estimates for the overall risk of malignancy and for individual cancers with the exception of uterine cancer. This loss of a risk association with uterine cancer suggests that PCOS/endometriosis may confound the relationship between infertility and uterine cancer. Another potential common mechanism between cancer and infertility is the presence of mutations in genes associated with DNA repair (e.g. BRCA) that may increase the risk of both conditions (Giordano et al., 2016; Johnson et al., 2017) . In summary, our findings suggest an association between infertility and higher risk of cancer compared to a population deemed by claimsbased criteria to be non-infertile.
In a subset analysis, we compared outcomes of women in each cohort who became pregnant and had a delivery during the enrollment period. A higher proportion of the infertile cohort underwent pregnancy and delivery during the enrollment period than the non-infertile cohort. This is likely multifactorial in nature and may be due to noninfertile women already completing their family prior to the index date and/or not attempting to become pregnant during the enrollment period. In addition, a higher proportion of both the infertile cohort and non-infertile cohort who had a child during the enrollment period were nulliparous compared to the overall cohort. This subset of patients were younger than the overall cohort and likely had a higher prevalence of primary infertility. In patients who became pregnant and had a delivery, several risk associations that were noted in the overall comparison were diminished. Namely, the risk of developing ovarian, uterine, lung, liver and gallbladder cancer were similar between the subset of infertile and non-infertile patients who became pregnant with a subsequent delivery but were elevated in the overall comparison of infertile women to non-infertile women. As some of these cancers are hormone mediated, it does suggest a possible mechanism behind the seemingly protective effect of childbearing among infertile women who succeed in fertility treatment. It is important to note that cancers in reproductive age women are, overall, rare events and the conclusions of our subgroup analysis are limited by the low incidence of the outcomes of interest. Our findings are in accordance with previous reports that parity is associated with a reduction in the risk of ovarian and uterine cancer (Adami et al., 1994; Lambe et al., 1999) . Pregnancy resulting in delivery has also been shown to be protective against breast cancer (Dupont and Page, 1987) . We report no association between breast cancer risk in either the overall infertile cohort or the subset of infertile patients with a delivery. The effect of pregnancy on non-hormone sensitive cancers is not as clearly established. No clear association has been reported between prior live births and lung cancer risk (Kreuzer et al., 2003) . The role of estrogen in the development of hepatic adenomas has been well established and by extension the role of reproductive hormones in development of liver cancer has been hypothesized but not clearly demonstrated (Nagasue et al., 1986; Giannitrapani et al., 2006) . In order to elucidate if infertility treatment or childbearing are responsible for reducing risk associations with cancer, future studies would examine outcomes of infertile patients who conceive spontaneously versus with fertility treatment.
Study limitations
While the number of patients and total person-years of follow up was high, one of the limitations of the study is the low incidence of cancer outcomes in reproductive age women. Furthermore, population health level databases are subject to a variety of limitations. While the number of total person years of follow up is large, the average number of years of follow up for each patient and their age at index date were limited. It is of note, however, that several significant risk associations were noted in a short duration of follow up. It is not known whether factors related to population turnover in the database are related to cancer risk, and thus is a source of potential bias. We did perform a sensitivity analysis limited to women with progressively longer follow up to determine how shorter follow up affected results. We identified similar point estimates in these analyses. Furthermore, the limited follow up time in our study inadvertently selects for the subset of cancers that present at an early age. Future studies would incorporate longer term follow up after infertility diagnosis or initiation of fertility treatment in order to more effectively capture these rare outcomes. While we controlled for several covariates in our data analysis, our ability to capture some was limited. For example, nulliparous status is not consistently identified by insurance claims data. In addition, we could not distinguish between a history of smoking and current smoking status. While the Optum ® Data Mart data comprises both commercial and
Medicare Advantage health plan data from a geographically diverse population, there is selection bias of the population as a whole as they are all insured. The selection of patients for the infertile and noninfertile cohorts is subject to some limitations. Estimates of the prevalence of infertility are around 10% (Chandra et al., 2013) , while in our study population~2% of women were infertile. Infertility may have been undercounted, for example, among nulliparous women in the non-infertile cohort who were utilizing contraception and therefore do not have proven fertility. In addition, while the majority of inseminations included are likely utilizing partner sperm, we are unable to distinguish these from donor insemination cycles in which only a portion of women are infertile. We expect, however, that misclassification would be non-differential which would shift results towards the null so any association we identify is likely to be underestimated. Future studies would separately examine the incidence of cancer in women diagnosed with infertility compared to infertile women who subsequently undergo fertility treatment. Details regarding infertility diagnosis and treatment are not fully captured in insurance claims data, therefore we did not separately analyze risk associations with infertility diagnosis versus treatment. For example, patients could have sought fertility treatment outside of insurance coverage. This would have not been captured in our database and led to non-differential misclassification with a regression to a null finding. Despite this likely underestimate of associations, we still found differences between the overall infertile and non-infertile cohorts. While we included women utilizing contraception in the non-infertile cohort, we did not account for potential risk modification associated with IUD and oral contraceptive use (Cramer, 2012) . Future studies would control for potential confounders including oral and long-acting contraceptive use, BRCA diagnosis, age at first birth, and oligomenorrhea, which may affect both fertility and cancer risk. As the database we utilized was de-identified, linkage to national registries and death certificates was not possible. While we did include inpatient and outpatient claims data, care received outside the insurance system or care that was incorrectly coded would be missed. The limitations of claims-based data have been previously described (Roos et al., 1993) ; in the absence of linkage to a population-based registry, we are unable to distinguish subject misidentification or loss of continuity. For example, we were not able to separately identify women diagnosed with infertility who then conceive spontaneously. This would require linking ART treatment records to birth certificates, a level of granularity that we were not able to access in the de-identified database, and thus is a potential source of detection bias. Finally, due to the high number of cancer outcomes investigated, there is a possibility that a small fraction of the results are false positives due to the role of chance. We investigated 17 individual cancers and found 6 positive associations. Chance alone may account for one false positive but would be unlikely to explain all of them. Using claims-based data, we report that infertility is associated with a higher risk of cancer compared to a group of non-infertile women. From a subset analysis, we report that infertile women who conceive may have a lower risk of certain malignancies, namely uterine and ovarian cancers. While the absolute increase in cancer risk with infertility is small, this increase was seen within only 4 years of infertility diagnosis, strongly supporting the need for further study to determine what factors influence the long-term cancer risk for infertile women.
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